TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07536282: Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

Sponsor: Newish Biotech (Wuxi) Co., Ltd. · Phase: PHASE1/PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 78 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,996,800

Rescue Site Savings

+$5,272,890

Unlock Full NCT07536282 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07536282 Rescue Dossier →